MktsMarkets

Fennec Pharmaceuticals Inc.
NASDAQ: FENCKey statistics
FENC News
Stories mentioning FENC from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 15,108 | 13,777 | 12,462 | 9,652 | 8,751 | 7,925 | 6,974 | 7,262 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 49.00 | 20.00 | 29.00 | 107.00 | 94.00 | 50.00 | 97.00 | 157.00 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 15,227 | 16,330 | 12,651 | 12,384 | 9,559 | 8,859 | 12,176 | 12,301 |
| Operating Income (Loss) | (119.00) | (2,553) | (189.00) | (2,732) | (808.00) | (934.00) | (5,202) | (5,039) |
| Interest Income | 339.00 | 228.00 | 152.00 | 171.00 | 236.00 | 399.00 | 516.00 | 570.00 |
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | 201.00 | (4,786) | (638.00) | (3,152) | (1,165) | (1,985) | (5,735) | (5,553) |
| Earnings Per Share (Basic) | 0.01 | (0.17) | (0.02) | (0.11) | (0.04) | (0.07) | (0.21) | (0.20) |
| Earnings Per Share (Diluted) | 0.01 | (0.17) | (0.02) | (0.11) | (0.04) | (0.07) | (0.21) | (0.20) |
| Weighted Average Shares Outstanding (Basic) | 34,336 | 28,577 | 27,889 | 27,664 | 27,578 | 27,294 | 27,371 | 27,297 |
| Weighted Average Shares Outstanding (Diluted) | 35,548 | 28,577 | 27,889 | 27,664 | 27,578 | 27,294 | 27,371 | 27,297 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About FENC
Fennec Pharmaceuticals Inc. (NASDAQ: FENC) is a stock listed on the Nasdaq Stock Market under the ticker symbol FENC. It last traded at $12.56 (Nov 16, 2026, 10:25 AM ET), up 8.1% on the day. That gives Fennec Pharmaceuticals a market capitalisation of $407.5M.
Over the past 52 weeks FENC has traded between $5.65 and $13.25.
Revenue for the quarter ended Mar 31, 2026 was $15.1M; net income $201.0K. Revenue was up 72.6% from $8.8M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $15.1M | $201.0K | 1.3% |
| Dec 31, 2025 | $13.8M | -$4.8M | -34.7% |
| Sep 30, 2025 | $12.5M | -$638.0K | -5.1% |
| Jun 30, 2025 | $9.7M | -$3.2M | -32.7% |
From Fennec Pharmaceuticals’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…